Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Non Operating Investment Income (2025 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non Operating Investment Income for 2 consecutive years, with -$60663.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Investment Income changed N/A to -$60663.0 in Q4 2025 year-over-year; TTM through Oct 2025 was -$98810.0, a 76.25% increase, with the full-year FY2025 number at $66316.0, changed N/A from a year prior.
  • Non Operating Investment Income was -$60663.0 for Q4 2025 at PharmaCyte Biotech, up from -$104463.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $72632.0 in Q1 2025 to a low of -$416000.0 in Q1 2024.